Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension
In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined. Thirty-seven patients and 30 age and body mass index matched healthy controls were follo...
Gespeichert in:
| Veröffentlicht in: | Anadolu kardiyoloji dergisi : AKD 2014-05, Vol.14 (3), p.234-238 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 238 |
|---|---|
| container_issue | 3 |
| container_start_page | 234 |
| container_title | Anadolu kardiyoloji dergisi : AKD |
| container_volume | 14 |
| creator | Meriç, Coşkun Aydoğdu, Aydoğan Taşçı, İlker Deniz, Ferhat Baysan, Oben Serdar, Muhittin Sağlam, Kenan Azal, Ömer |
| description | In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined.
Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively. Serum ghrelin level was measured by enzyme immunoassay (EIA). Left ventricular mass was determined by transthoracic echocardiography. Left ventricular mass index (LVMI) was calculated by dividing the left ventricular mass to body surface area. All patients were started treatment with oral valsartan 80 mg. Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction. At the end of the 12th week all measurements were repeated in the patient group. All data were recorded in the computer using SPSS for Windows software. Mann-Whitney U, Student t, Wilcoxon and t tests were used for statistical analyses.
At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p |
| doi_str_mv | 10.5152/akd.2014.4738 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1537182999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3568599041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c251t-fdcc5d8adce1a90e70af91541a16df5e3a77cf2eaecfc5cfd51cd9c2f7029eb63</originalsourceid><addsrcrecordid>eNpdkT1v2zAQhomiQe0mHbsGBLJ0kUNSoiiNgeF-AAa6JDNxIY-1XIlySMpJfkD_d-jYydCFdwAfvDzeQ8hXzhaSS3ENf-1CMF4tKlU2H8icl6wpGCvFx9deFI0S5Yx8jnHLmFS1qj6RmahkXctKzcm_lXNoUqSjo3voI4QEnqaAkAb0iY6eRgzTQP9sAvadpz3usafgbe5covsMhc5MPQQ6QIy08xaf8kl3kLp8GeljlzZ08q-ZaOkudAOEZ7p53mFI6GM3-gty5vLj-OVUz8nd99Xt8mex_v3j1_JmXRgheSqcNUbaBqxBDi1DxcC1XFYceG2dxBKUMk4goHFGGmclN7Y1wikmWryvy3Py7Zi7C-PDhDHpoYsG-x48jlPUXJaKN6Jt24xe_Yduxyn4PJ3mddWww_6qTBVHyoQxxoBOn76nOdMHPzr70Qc_-uAn85en1Ol-QPtOvwkpXwDBGo_0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1648066544</pqid></control><display><type>article</type><title>Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Meriç, Coşkun ; Aydoğdu, Aydoğan ; Taşçı, İlker ; Deniz, Ferhat ; Baysan, Oben ; Serdar, Muhittin ; Sağlam, Kenan ; Azal, Ömer</creator><creatorcontrib>Meriç, Coşkun ; Aydoğdu, Aydoğan ; Taşçı, İlker ; Deniz, Ferhat ; Baysan, Oben ; Serdar, Muhittin ; Sağlam, Kenan ; Azal, Ömer</creatorcontrib><description>In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined.
Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively. Serum ghrelin level was measured by enzyme immunoassay (EIA). Left ventricular mass was determined by transthoracic echocardiography. Left ventricular mass index (LVMI) was calculated by dividing the left ventricular mass to body surface area. All patients were started treatment with oral valsartan 80 mg. Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction. At the end of the 12th week all measurements were repeated in the patient group. All data were recorded in the computer using SPSS for Windows software. Mann-Whitney U, Student t, Wilcoxon and t tests were used for statistical analyses.
At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p<0.05). After a 12-week antihypertensive treatment of patients, serum ghrelin concentration increased while LVMI decreased (p<0.05, for both). No significant correlation was found between Δ-ghrelin level and Δ-LVMI (r=0.155, p=0.368).
Low circulating level of ghrelin in patients with hypertension and its increase after antihypertensive treatment suggest that this peptide need to be explored in the mechanism and complications of hypertension.</description><identifier>ISSN: 1302-8723</identifier><identifier>ISSN: 2149-2263</identifier><identifier>EISSN: 1308-0032</identifier><identifier>EISSN: 2149-2271</identifier><identifier>DOI: 10.5152/akd.2014.4738</identifier><identifier>PMID: 24566547</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><subject>Administration, Oral ; Adult ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - therapeutic use ; Case-Control Studies ; Echocardiography ; Enzyme-Linked Immunosorbent Assay ; Female ; Ghrelin - blood ; Humans ; Hypertension - blood ; Hypertension - drug therapy ; Hypertrophy, Left Ventricular - diagnostic imaging ; Hypertrophy, Left Ventricular - drug therapy ; Hypertrophy, Left Ventricular - pathology ; Male ; Prospective Studies ; Treatment Outcome ; Valsartan - administration & dosage ; Valsartan - therapeutic use</subject><ispartof>Anadolu kardiyoloji dergisi : AKD, 2014-05, Vol.14 (3), p.234-238</ispartof><rights>Copyright Aves Yayincilik Ltd. STI. May 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c251t-fdcc5d8adce1a90e70af91541a16df5e3a77cf2eaecfc5cfd51cd9c2f7029eb63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24566547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meriç, Coşkun</creatorcontrib><creatorcontrib>Aydoğdu, Aydoğan</creatorcontrib><creatorcontrib>Taşçı, İlker</creatorcontrib><creatorcontrib>Deniz, Ferhat</creatorcontrib><creatorcontrib>Baysan, Oben</creatorcontrib><creatorcontrib>Serdar, Muhittin</creatorcontrib><creatorcontrib>Sağlam, Kenan</creatorcontrib><creatorcontrib>Azal, Ömer</creatorcontrib><title>Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension</title><title>Anadolu kardiyoloji dergisi : AKD</title><addtitle>Anadolu Kardiyol Derg</addtitle><description>In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined.
Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively. Serum ghrelin level was measured by enzyme immunoassay (EIA). Left ventricular mass was determined by transthoracic echocardiography. Left ventricular mass index (LVMI) was calculated by dividing the left ventricular mass to body surface area. All patients were started treatment with oral valsartan 80 mg. Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction. At the end of the 12th week all measurements were repeated in the patient group. All data were recorded in the computer using SPSS for Windows software. Mann-Whitney U, Student t, Wilcoxon and t tests were used for statistical analyses.
At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p<0.05). After a 12-week antihypertensive treatment of patients, serum ghrelin concentration increased while LVMI decreased (p<0.05, for both). No significant correlation was found between Δ-ghrelin level and Δ-LVMI (r=0.155, p=0.368).
Low circulating level of ghrelin in patients with hypertension and its increase after antihypertensive treatment suggest that this peptide need to be explored in the mechanism and complications of hypertension.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Echocardiography</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Ghrelin - blood</subject><subject>Humans</subject><subject>Hypertension - blood</subject><subject>Hypertension - drug therapy</subject><subject>Hypertrophy, Left Ventricular - diagnostic imaging</subject><subject>Hypertrophy, Left Ventricular - drug therapy</subject><subject>Hypertrophy, Left Ventricular - pathology</subject><subject>Male</subject><subject>Prospective Studies</subject><subject>Treatment Outcome</subject><subject>Valsartan - administration & dosage</subject><subject>Valsartan - therapeutic use</subject><issn>1302-8723</issn><issn>2149-2263</issn><issn>1308-0032</issn><issn>2149-2271</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkT1v2zAQhomiQe0mHbsGBLJ0kUNSoiiNgeF-AAa6JDNxIY-1XIlySMpJfkD_d-jYydCFdwAfvDzeQ8hXzhaSS3ENf-1CMF4tKlU2H8icl6wpGCvFx9deFI0S5Yx8jnHLmFS1qj6RmahkXctKzcm_lXNoUqSjo3voI4QEnqaAkAb0iY6eRgzTQP9sAvadpz3usafgbe5covsMhc5MPQQ6QIy08xaf8kl3kLp8GeljlzZ08q-ZaOkudAOEZ7p53mFI6GM3-gty5vLj-OVUz8nd99Xt8mex_v3j1_JmXRgheSqcNUbaBqxBDi1DxcC1XFYceG2dxBKUMk4goHFGGmclN7Y1wikmWryvy3Py7Zi7C-PDhDHpoYsG-x48jlPUXJaKN6Jt24xe_Yduxyn4PJ3mddWww_6qTBVHyoQxxoBOn76nOdMHPzr70Qc_-uAn85en1Ol-QPtOvwkpXwDBGo_0</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Meriç, Coşkun</creator><creator>Aydoğdu, Aydoğan</creator><creator>Taşçı, İlker</creator><creator>Deniz, Ferhat</creator><creator>Baysan, Oben</creator><creator>Serdar, Muhittin</creator><creator>Sağlam, Kenan</creator><creator>Azal, Ömer</creator><general>Kare Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension</title><author>Meriç, Coşkun ; Aydoğdu, Aydoğan ; Taşçı, İlker ; Deniz, Ferhat ; Baysan, Oben ; Serdar, Muhittin ; Sağlam, Kenan ; Azal, Ömer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c251t-fdcc5d8adce1a90e70af91541a16df5e3a77cf2eaecfc5cfd51cd9c2f7029eb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Echocardiography</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Ghrelin - blood</topic><topic>Humans</topic><topic>Hypertension - blood</topic><topic>Hypertension - drug therapy</topic><topic>Hypertrophy, Left Ventricular - diagnostic imaging</topic><topic>Hypertrophy, Left Ventricular - drug therapy</topic><topic>Hypertrophy, Left Ventricular - pathology</topic><topic>Male</topic><topic>Prospective Studies</topic><topic>Treatment Outcome</topic><topic>Valsartan - administration & dosage</topic><topic>Valsartan - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meriç, Coşkun</creatorcontrib><creatorcontrib>Aydoğdu, Aydoğan</creatorcontrib><creatorcontrib>Taşçı, İlker</creatorcontrib><creatorcontrib>Deniz, Ferhat</creatorcontrib><creatorcontrib>Baysan, Oben</creatorcontrib><creatorcontrib>Serdar, Muhittin</creatorcontrib><creatorcontrib>Sağlam, Kenan</creatorcontrib><creatorcontrib>Azal, Ömer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Anadolu kardiyoloji dergisi : AKD</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meriç, Coşkun</au><au>Aydoğdu, Aydoğan</au><au>Taşçı, İlker</au><au>Deniz, Ferhat</au><au>Baysan, Oben</au><au>Serdar, Muhittin</au><au>Sağlam, Kenan</au><au>Azal, Ömer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension</atitle><jtitle>Anadolu kardiyoloji dergisi : AKD</jtitle><addtitle>Anadolu Kardiyol Derg</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>14</volume><issue>3</issue><spage>234</spage><epage>238</epage><pages>234-238</pages><issn>1302-8723</issn><issn>2149-2263</issn><eissn>1308-0032</eissn><eissn>2149-2271</eissn><abstract>In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined.
Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively. Serum ghrelin level was measured by enzyme immunoassay (EIA). Left ventricular mass was determined by transthoracic echocardiography. Left ventricular mass index (LVMI) was calculated by dividing the left ventricular mass to body surface area. All patients were started treatment with oral valsartan 80 mg. Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction. At the end of the 12th week all measurements were repeated in the patient group. All data were recorded in the computer using SPSS for Windows software. Mann-Whitney U, Student t, Wilcoxon and t tests were used for statistical analyses.
At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p<0.05). After a 12-week antihypertensive treatment of patients, serum ghrelin concentration increased while LVMI decreased (p<0.05, for both). No significant correlation was found between Δ-ghrelin level and Δ-LVMI (r=0.155, p=0.368).
Low circulating level of ghrelin in patients with hypertension and its increase after antihypertensive treatment suggest that this peptide need to be explored in the mechanism and complications of hypertension.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>24566547</pmid><doi>10.5152/akd.2014.4738</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1302-8723 |
| ispartof | Anadolu kardiyoloji dergisi : AKD, 2014-05, Vol.14 (3), p.234-238 |
| issn | 1302-8723 2149-2263 1308-0032 2149-2271 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1537182999 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Administration, Oral Adult Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use Case-Control Studies Echocardiography Enzyme-Linked Immunosorbent Assay Female Ghrelin - blood Humans Hypertension - blood Hypertension - drug therapy Hypertrophy, Left Ventricular - diagnostic imaging Hypertrophy, Left Ventricular - drug therapy Hypertrophy, Left Ventricular - pathology Male Prospective Studies Treatment Outcome Valsartan - administration & dosage Valsartan - therapeutic use |
| title | Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20valsartan%20treatment%20on%20serum%20ghrelin%20level%20and%20left%20ventricular%20mass%20index%20in%20patients%20with%20untreated%20primary%20hypertension&rft.jtitle=Anadolu%20kardiyoloji%20dergisi%20:%20AKD&rft.au=Meri%C3%A7,%20Co%C5%9Fkun&rft.date=2014-05-01&rft.volume=14&rft.issue=3&rft.spage=234&rft.epage=238&rft.pages=234-238&rft.issn=1302-8723&rft.eissn=1308-0032&rft_id=info:doi/10.5152/akd.2014.4738&rft_dat=%3Cproquest_cross%3E3568599041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1648066544&rft_id=info:pmid/24566547&rfr_iscdi=true |